[Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].

CONCLUSIONS: Telaprevir-related dermatitis has a high incidence but is mostly of mild intensity. In most cases, tri-therapy was continued under close dermatological follow-up allowing rapid detection of rare instances of severe drug eruptions. Ribavirin and Interferon were thus continued even in the event of diffuse eruptions, enabling confirmation of the causative role of telaprevir in these eruptions. PMID: 27161648 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27161648?dopt=Abstract

Source: Annales de Dermatologie et de Cenereologie - May 5, 2016 Category: Dermatology Authors: Lorcy S, Gaudy-Marqueste C, Botta D, Portal I, Quiles N, Oulies V, Mancini J, Grob JJ, Richard MA Tags: Ann Dermatol Venereol Source Type: research